This initiative, for instance, notes that for difficult-to-treat severe asthma characterized by eosinophilia or elevated FeNO, the addition of a biologic, such as dupilumab, alongside anti-IL-5 or anti-IgE options, should be considered after a scrutinized specialist assessment (Wechsler et al., 2022). This evidence concerns the gene IGHE and asthma.